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I was born in 1946 and grew up in the industrial north-west of
England close to the city of Manchester. My  parents were German-
Jewish refugees, who left Germany fairly early, in 1933. My  father
helped to establish and was one of the directors of a tannery, which
made leather for shoes and handbags. This was part of a group of
tanneries established ﬁrst in Strasbourg by my  great-grandfather
Ferdinand Oppenheimer. I would describe my  childhood and ado-
lescent years as comfortable by general post-war standards. I went
to a state primary school and obtained a scholarship to Manchester
Grammar School (MGS), a fairly prestigious secondary school. As
a child I was always interested in chemistry but had little interest
in or knowledge of biology. The educational system in the UK at
that time was such that one had to specialise very early and as a
consequence I have had no formal biology education since the age
of 12, something I have managed to hide reasonably successfully
for the rest of my  life! In my  ﬁnal two years at MGS I studied just
physics, chemistry and mathematics and obtained a scholarship to
Pembroke College, Cambridge (England) to study Natural Sciences,
with the intention of becoming a chemist. In the second year at
Cambridge, one of the options was a course on biochemistry. Hav-
ing no real idea what this was, I read a book about it in the summer
of 1965, and was truly astonished and excited to discover that the
basis of life was just a bunch of rather complicated organic chem-
istry reactions. So I took the biochemistry course in my  second year.
By the end of that year, I was fed up with chemistry and for my  ﬁnal
year I chose to do biochemistry rather than chemistry, a decision
I have not regretted. The biochemistry lectures must have been
pretty up-to-date, as we were told brieﬂy about the discovery of
DNA repair by Dick Setlow [1],  a topic that seemed rather esoteric
at the time.
1. PhD and postdoc: London, Tennessee and Sussex
In early 1967, in my  ﬁnal year at Cambridge, I saw an advertise-
ment for a PhD position at the Chester Beatty Research Institute in
London and went for an interview with Professor Peter Alexander,
Christopher Dean and John Lett, a group of well-known radiobiolo-
gists. The work they proposed, to measure repair of double-strand
breaks in mammalian cells, sounded interesting and I was, as it
turned out erroneously, offered a place without any conditions.
PhD positions are always offered on condition of obtaining a ﬁrst
or upper second class degree. Although I was expected to, and
indeed went on to get a ﬁrst-class degree, I decided that a bird
in the hand was  worth two in the bush and accepted the offer,
another decision that I did not regret. I started my PhD studies in a
new building in South London in October 1967 to discover that my
proposed supervisor, John Lett, had taken a job in USA  and his suc-
cessor was  a radiation physicist, Mike Ormerod. I was actually the
only biochemist in the small department and this, together with
my Cambridge degree, gave me  a certain status above my  station.
Another important event that took place at the end of that year
was my  marriage, at what now seems like the ludicrously tender
age of 21, to Judy Selbourne, a history graduate also from Manch-
ester. This was  a third decision I have not regretted and we have
now been married for 43 years!
Measuring double-strand breaks was  not easy. In 1967 McGrath
and Williams had shown that single-strand breaks could be anal-
ysed by lysing bacterial cells on top of alkaline sucrose gradients
and spinning out the denatured DNA strands in the ultracentrifuge
[2]. The number of single-strand breaks could be measured from
the rate of sedimentation of the DNA fragments. The Chester Beatty
group had shown that this technique could also be applied to mam-
malian cells [3],  and my  job was  to do similar measurements using
neutral sucrose gradients to measure double-strand breaks. I was
able to obtain a peak of fragmented DNA without difﬁculty. Unfor-
tunately the position of the DNA remained the same, irrespective
of the dose to which the cells were exposed, over a dose-range
of 300–2000 Gy. In other words, it appeared that over a 10-fold
dose range, there was  no change in the apparent number of double-
strand breaks. I struggled for a year trying to solve this mysterious
phenomenon before temporarily abandoning the project.
1968 saw a great leap forward in the ﬁeld of DNA replication
with the discovery of Okazaki fragments in Escherichia coli [4],  and
this was followed by a similar claim for mammalian cells [5].  We
realised however that the results obtained did not actually measure
Okazaki fragments but were instead a consequence of a labelling
artefact. This led to my  ﬁrst paper being a short note in Nature [6]
(Fig. 1A) – the only ﬁrst/last author paper I have managed to publish
in Nature! It turned out of course that Okazaki fragments did indeed
exist in mammalian cells, but the paper with the ﬁrst claim was
deﬁnitely wrong. We  completed a mathematical analysis of this
labelling artefact and were able to use it in a more positive way  to
measure the rate of replication fork progression in mouse cells [7].
At about that time, I came across a paper on centrifugation of high
molecular weight DNA, showing that if DNA is centrifuged at high
speeds, the rotor speed could affect sedimentation rates of DNA.
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Fig. 1. (A) A page from my  ﬁrst paper, which, like the author, is showing signs of wear and tear forty years later (B, 1970; C, 2010).
I rushed back from the library, repeated my  double-strand break
experiments, but now ran the centrifuge at 10,000 rpm rather than
40,000 rpm and, look and behold, I obtained a nice dose–response
for the induction of double-strand breaks and was able to show that
this was linear for X-irradiation of mouse cells from 300–4000 Gy
[8]. I did not detect any repair, most likely because I was  using such
high radiation doses. Unfortunately at lower doses, the DNA formed
an aggregate and could not be analysed. My  PhD work ﬁnished with
an analysis of replicon sizes in mouse cells, again using alkaline
sucrose gradients [9].
In the 1960–1970s getting one’s BTA (Been To America) was
de rigeur for a scientiﬁc career in the UK and Peter Alexander
suggested I go to the lab of Dick Setlow, who  had discovered
excision-repair a few years earlier. Dick was kind enough to accept
me  for a postdoctoral position in his lab in Oak Ridge, Tennessee,
in 1970. We  arrived at Knoxville, Tennessee, airport in September
1970, laden with luggage and wearing our thick English overcoats
so as not to ﬁll up valuable luggage space. As the temperature was
about 28 ◦C and the humidity close to 100%, Dick did not have too
much trouble identifying us. Coming from London, arrival in Ten-
nessee was something of a culture shock – we quickly learned that
going more than 100 m on foot was considered by the locals to
be close to insanity if you were able to travel by car. In the lab,
things were also pretty different. I had been used to chatting to
Mike Ormerod every day about my  work during my  PhD thesis,
whereas Dick Setlow was very much hands-off. I ﬂoundered around
for about 3 months searching for a decent project and getting a little
despondent, before latching onto a topic that was to occupy much
of my  future career.
Dean Rupp and Paul Howard-Flanders had published their sem-
inal work on postreplication repair in E. coli a couple of years earlier,
in which they demonstrated daughter-strand gaps in UV-irradiated
cells and showed that these gaps were subsequently sealed [10]. I
thought it would be interesting to look if something similar hap-
pened in mammalian cells. Shortly after starting this project, I had
the good fortune to attend the Biophysical Society meeting in New
Orleans in February 1971, where I met  Dean Rupp, Paul Howard-
Flanders, Phil Hanawalt and other luminaries in the DNA repair
ﬁeld. I learned about the elegant experiments of Rupp and col-
leagues, in which they demonstrated that ﬁlling of daughter strand
gaps in E. coli was effected by sister strand exchanges [11]. Dick Set-
low had developed an elegant procedure for measuring gap sizes
during nucleotide excision repair, by allowing the cells to incor-
porate bromodeoxyuridine (BrdU) into the gaps. BrdU-containing
DNA is susceptible to breakage by UV light of 313 nm, so the ﬁlled-in
gaps could be reconverted into breaks, and the size of the ﬁlled-in
gap was  inversely proportional to the dose of 313 nm irradiation
needed to cleave the patch [12,13]. I realised that I could adapt
this method to measure the size of daughter strand gaps during
postreplication repair (PRR) and to determine whether the gaps
were ﬁlled in by recombination with parental DNA, in which case
they would not contain BrdU and would not be cleavable by 313 nm
light. Alternatively if they were ﬁlled in by some kind of direct syn-
thesis (that we now call translesion synthesis (TLS)) they would be
cleavable. My  results favoured the latter mechanism and argued
against gap-ﬁlling by recombination in mammalian cells. To this
day, I feel that this was  the smartest experiment that I have done
through my  career, and I was excited to get it published in J. Mol.
Biol. [14], at the time one of the top journals. (Even in those days,
getting papers published in the best journals was  important – I
remember Mike Ormerod and I ranting about the stupid editor who
had rejected one of our papers during my  PhD. Le plus c¸ a change!)
Dick Setlow gave me  the opportunity to present my  data at the
Gordon Conference on Nucleic Acids that he was chairing in the
summer of 1971. I remember Paul Howard-Flanders giving me a
hard time about interpretation of my  data, but I got to meet another
bunch of contemporary DNA repair stars such as Larry Grossman,
and up and coming ones like Errol Friedberg and Priscilla Cooper.
My year in the US was  highly formative and by the end of it, I had
met  almost everyone who was  anyone in the DNA repair ﬁeld and
had generated data for two  nice papers. That would certainly be
extremely difﬁcult nowadays. We  returned to the UK in September
1971 and had to make cultural re-adjustments to small cars, public
transport and gardens with roses. I had arranged a second postdoc
at the University of Sussex with Sydney Shall. Sussex was one of a
group of universities that were set up in the UK in the 1960s and it
had established a good academic reputation in a few years as well
as being regarded as pretty avant-garde. One  reason I had chosen
Sussex was  that the professor of biochemistry, Asher Korner, had
taught me  about protein synthesis when I was an undergraduate
at Cambridge and had particularly impressed me. I was distressed
to discover on my  arrival at Sussex that he had died very suddenly
a few weeks earlier while only in his early 40s.
Sydney Shall was  one of the ﬁrst people to work on PARP, which
at that time was  a novel polymer of completely unknown function.
For the next two  years I dabbled a bit in studying PARP [15] as well
as consolidating my  work on PRR. I was singularly unimpressed and
dismissive when Sydney suggested that PARP might be involved in
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Fig. 2. 1975–1976. (A) Members of the CMU  in 1976. Note: The shack which housed the labs, the author in more hirsute days (far left), Colin Arlett and Bryn Bridges (back
row,  right). (B) Figure from our 1975 PNAS paper, showing the dramatic difference in the size of newly synthesised DNA in UV-irradiated normal and XPV cells in the presence
of  caffeine (indicated by arrows).
DNA repair, which does not say much for my  vision or instinct!
After I had left his lab, he went on to show that PARP inhibitors do
indeed sensitise cells to DNA damage [16] and the rest is history.
In 1970, Bryn Bridges had established a small Medical Research
Council-funded Unit, the MRC  Cell Mutation Unit (CMU) on the Uni-
versity of Sussex campus. It was housed in a wood and glass shack
(Fig. 2A), just across the way from the School of Biological Sciences,
where I was working. One day in the summer of 1973 Bryn and
Colin Arlett approached me  after a seminar, told me  that one of
their four-man scientiﬁc staff was leaving and offered me  the job.
Recruitment was rather simpler in those days – no HR department,
no obligatory advertising and interviewing. If you found someone
you wanted to hire, you just hired them. Needless to say, I jumped
at the opportunity and stayed at the CMU  for the next 28 years –
though we did graduate to a real brick building in 1980. 1973 was
also a major milestone for us domestically with the birth of our son,
Paul, to be followed a few years later by our daughter Anna.
2. XP variants, Cockayne syndrome and other
repair-deﬁcient disorders
My  new colleague at the CMU, Colin Arlett, a mammalian cell
biologist, was about to embark on studying the effects of DNA dam-
aging agents on primary human ﬁbroblasts, on which few people
were working at that time. Jim Cleaver had discovered the defect
in excision repair of UV damage in xeroderma pigmentosum (XP)
in1968 [17], but in 1971, Jay Robbins and colleagues identiﬁed a XP
patient with normal repair, which they designated as an XP vari-
ant [18], and Dirk Bootsma and colleagues identiﬁed another two
of these XP variants [19]. Taking advantage of Colin’s cell culture
expertise, I decided to look if PRR was defective in XP variants. As
it happens, we had just started what was to become an almost 40-
years’ collaboration with the DNA repair labs of Dirk Bootsma and
then Jan Hoeijmakers in Rotterdam and of Paul Lohman followed by
Leon Mullenders in Rijswijk and later in Leiden in the Netherlands.
This collaboration blossomed over that period and was  extended
to include other major DNA repair labs in Europe. We  were able to
obtain European Union funding for collaborative projects over the
next 35 years, as well as establishing the 5-yearly DNA repair meet-
ings in the Netherlands – the most recent of which took place just
last month (April, 2011). These collaborations played a major role in
establishing and maintaining the prominent role of European labs
in the DNA repair ﬁeld.
To return to the XP-V story, Dirk Bootsma supplied us with
their XP variant ﬁbroblast strains and my  technician, Sue Kirk-Bell,
carried out many more sucrose gradient experiments, the sum of
which did indeed indicate that XP-V cells were defective in PRR.
Caffeine had been shown to sensitise cells to various DNA damag-
ing agents and this had been extensively studied in rodent cells by
Mike Rauth (e.g. [20]). Additionally I and others had shown that
caffeine inhibited PRR in rodent cells [21]. Remarkably, we found
that it had no effect on PRR in normal human ﬁbroblasts, but com-
pletely inhibited the already deﬁcient PRR in XPV ﬁbroblasts, thus
generating a huge difference between the normal and XPV cells
[22]. In 1970s, effects of caffeine were interpreted in terms of its
inhibitory effects on cyclic AMP  phosphodiesterase, whereas these
days everybody thinks of it as an inhibitor of ATR and ATM. I am
pretty convinced that its effect on PRR is independent of both of
these – it inhibits at low doses and its effect is immediate – and
that it acts more directly.
Dirk Bootsma was not convinced by our results and decided to
send us three samples without disclosing their origin. We  had now
optimised our protocol and were able immediately to identify them
as being normal, XPV and excision-defective XP. The data from that
blind experiment are shown in Fig. 4 of the paper that was  pub-
lished in PNAS in 1975 (see Fig 2B) [22] and is my most cited paper.
We then built on this work and spent a lot of time in the next
few years debating in the literature and at meetings whether the
replication fork was  blocked at lesions, whether it restarted beyond
the lesion after a delay, or whether synthesis bypassed the lesion
directly without discontinuities (e.g. [23]). These issues were not
resolved and by 1980, studies on PRR ran out of steam and the
whole ﬁeld effectively went to sleep for almost 20 years. However
these same questions are currently once again under investigation
in several labs (e.g. [24–26]).
After discovering the defect in XP variant cells, we  started to
contact clinicians to obtain samples from patients with other dis-
orders to see if they might have similar or other defects in DNA
repair. Most of these led nowhere, but there were a few notable
exceptions. In 1975 Bryn Bridges discussed our work with David
Harnden, the Head of the Department of Cancer Studies at Birming-
ham University and David sent down a young colleague, Malcolm
Taylor, with cells from three different disorders to look for possi-
ble DNA repair defects. One of these was  ataxia-telangiectasia and
together with Colin Arlett, Malcolm showed that they were sensi-
tive to ionising radiation [27], a discovery that sparked off a whole
new research area that led to the cloning of the ATM gene 20 years
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later [28]. I was a little disappointed that we found no evidence for a
defect in double-strand break repair using the relatively insensitive
techniques that were available at the time [27,29].
In 1977, we were visited by Roy Schmickel, a paediatrician from
Michigan, who introduced us to Cockayne syndrome. He informed
us that he and Ernest Chu had shown that CS cells were sensitive to
UV-irradiation, but had no defect in NER [30]. We  conﬁrmed these
observations as well as showing no defect in PRR. I reasoned that if
the cells were sensitive to UV using a colony-forming assay, which
gave results 3 weeks after irradiating the cells, we  must be able to
ﬁnd a defect earlier after irradiation. Being a great believer in sim-
ple experiments, I thought we could start off by simply measuring
the rate of DNA synthesis by thymidine incorporation after irradia-
tion. DNA synthesis was, as expected, inhibited by irradiation, but it
recovered after a few hours in normal cells. In contrast, in CS cells
the recovery did not happen [31]. We  seemed to be onto some-
thing. We  next showed that this could not be the primary defect as
we could still observe cellular sensitivity to UV in quiescent cells
that never divided after irradiation. So my  ﬁrst graduate student,
Lynne Mayne, analysed RNA synthesis, again by simply measuring
incorporation of uridine. Here the effect was even more dramatic
than for DNA synthesis. RNA synthesis was inhibited but recovered
very rapidly in normal cells, but again there was  no recovery in CS
cells. I cannot resist reproducing a few lines from the discussion of
our 1982 paper [32]: “It is conceivable, however, that transcription-
terminating lesions, i.e., those lesions in the transcribing regions of
DNA, are potentially more lethal than the bulk of the lesions, and
that these, comprising only a small fraction of the total damage
(<10%), may  be excised rapidly in normal cells by some special ER
mechanism. On this model, the CS gene product would control this
special ER pathway, but it would not be involved in overall ER”. I
was naturally pretty pleased with myself a few years later for hav-
ing predicted transcription-coupled repair, which was discovered
by Bohr, Hanawalt, Mellon and colleagues [33,34],  and its defect in
CS, which was shown by Mullenders and colleagues [35]. Equally
naturally I would have been even more pleased if we  had made
these discoveries ourselves!
Around the mid  1980s, I realised that our simple incorporation
tests could be used diagnostically to conﬁrm or exclude clinical
(and prenatal) diagnoses of XP and CS [36] and tried to persuade
our paymasters at MRC  to fund a technician to do this work. They
were extremely reluctant as they felt that this was work that should
be done by the National Health Service, not the Medical Research
Council. We  managed to persuade them that this work would gen-
erate valuable samples for research and after a long and depressing
afternoon, they reluctantly agreed to underwrite the salary of the
technician, but insisted that we recoup the money by charging clin-
icians for the tests. As it happened, this coincided with Margaret
Thatcher’s policy of marketisation of the Health Service, so although
I despised almost everything that she stood for, her policy perhaps
enabled our diagnostic service to be established. Over the interven-
ing years, we have received samples from over 1000 patients from
all over the world and have diagnosed over 110 cases of XP, 160
cases of CS and carried out 70 prenatal diagnoses for CS in affected
families. In the meantime, MRC  policy has changed and at our last
quinquennial review, we were told that this was just the kind of
translational work that MRC-funded scientists should be doing!!!
In 1982 David Webster, a clinical immunologist from London,
sent to Colin Arlett a sample from an immunodeﬁcient patient,
whose cells we designated 46BR. Ian Teo, Colin’s graduate student,
found that unlike XP and A-T cells, which were sensitive to spe-
ciﬁc groups of genotoxins, 46BR seemed to be moderately sensitive
to almost all of them [37]. This suggested to us that it might be
deﬁcient in a late step in repair processes, and indeed we found evi-
dence for defects in DNA ligation [38] and together with the Lindahl
group, we showed that 46BR had some features in common with
Bloom syndrome [39]. A couple of years later Barnes and Lindahl
cloned the human DNA ligase I gene [40] and looked for mutations
in Bloom syndrome. They did not ﬁnd any mutations in DNA lig-
ase I in Bloom syndrome, but they did discover that 46BR was  a
compound heterozygote for mutations in DNA ligase I [41]. 46BR
remains the only known patient with a defect in this protein and it
has proven very useful in understanding the role of DNA ligase I in
different processes.
3. DNA repair in Schizosaccharomyces pombe and the
Smc5-6 complex
In 1985, our colleagues in Rotterdam cloned the ﬁrst human NER
gene (ERCC1) by transfection of a hamster UV-sensitive mutant [42]
and went on to clone many more DNA repair genes using similar
techniques. I have to admit that we  were slow off the mark to har-
ness recombinant DNA technology to our research, and although
we  did make some contributions in the mutagenesis ﬁeld [43], they
were not of major signiﬁcance. In 1987 Melanie Lee and Paul Nurse
cloned the human CDC2 cDNA by its ability to complement the S.
pombe cdc2 mutant [44]. I thought this might be a good way to
clone human repair genes and had the good fortune to have some
S. pombe experts close at hand. Furthermore a bunch of S. pombe
“rad” mutants had been isolated in the mid  70s (reviewed in [45])
but very little had been done with them since that time. We  thought
it would be a good idea to clone a S. pombe repair gene ﬁrst and Mike
Fenech, who spent a year in my  lab, together with Felicity Watts,
Jo Murray and Tony Carr, succeeded in cloning the ﬁrst S. pombe
repair gene, rad4/cut5 [46]. We had the good fortune to be able
to hire Tony Carr in the CMU  in 1988 and within about 6 months
Tony together with Jo Murray and Felicity Watts cloned about ten
S pombe DNA repair genes and together, we spent the next few
years characterising them and assigning them to different path-
ways. These included genes involved in classical NER [47,48],  in a
second repair pathway peculiar to S. pombe and a few other organ-
isms [49], and in cell cycle checkpoints (e.g. [50]). Tony went on to
study the latter in great depth and rapidly became a world leader
in this area. In fact we  never did clone any human genes by com-
plementation of the S. pombe mutants and it is unlikely that this
approach would have been successful except perhaps with one or
two  simple genes. We  did however succeed in using degenerate
PCR to clone the human homolog of S. pombe rad2, which turned
out to be the nuclease subsequently named Fen1 [49].
One gene was  left as a poor relation in our study of S. pombe
repair genes and was  at the time called rad18 (though it is unre-
lated to S. cerevisiae RAD18). This gene was  analysed gradually in
the lab by a succession of summer students and visiting workers,
and even on occasion by my  own  fair hand. In 1994, we  had com-
pleted our analysis and sent a paper to Mol. Cell. Biol. on a protein
involved in recombination repair with some leucine zipper motifs.
It was  rejected. At about the same time, several reports appeared
in the literature, describing a new class of structural maintenance
of chromosome (SMC) proteins, which were present in complexes
involved in chromosome cohesion and condensation [51–53].  It
became clear to us that our Rad18 protein was closely related to the
SMC  proteins, so we  resubmitted the paper with little extra data to
Mol. Cell. Biol., who  now considered it extremely interesting and
it was  accepted in 1995 [54]. My  lab has worked inter alia on this
protein, now termed Smc6, for the last 15 years. We  discovered its
Smc  partner protein Smc5 [55], as well as four other members of
the Smc5-6 complex, Nse1-4 [56] and worked out how the various
components ﬁt together [56,57].  We  also have identiﬁed and anal-
ysed the orthologous complex in human cells [58] and generated
mice mutated in Smc6 (unpublished).
Alongside the S. pombe work, my  interest in human disorders
turned to trichothiodystrophy (TTD). Miria Stefanini had shown
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that photosensitive TTD patients were defective in NER, like XP
cells, and moreover were assigned to the XP-D complementation
group [59]. We  initiated a long-standing collaboration with Miria,
extending her ﬁndings [60] and speculating and trying to under-
stand how mutations in the XPD gene could result in such different
phenotypes in XP and TTD. We  still do not really know the com-
plete answer to this, though there have of course been some major
advances. The ﬁrst was the cloning of the ERCC2 gene by Christine
Webber and Larry Thompson and demonstration that this was the
XPD gene [61], the second was the seminal discovery by the group of
Jean-Marc Egly in collaboration with the Rotterdam group that XPB
and XPD were components of the transcription factor TFIIH, which
had two functions, in NER and transcription [62]. Following on from
these exciting ﬁndings we were able to identify the ﬁrst mutations
in the XPD gene, in TTD patients [63], and subsequently in many
others and, importantly, we were able to show that each mutation
site is disease-speciﬁc. R683W, found in the majority of XP patients
in the XP-D group, has never been found in a TTD patient, whereas,
R112H and R722W, fairly common in TTD, are never found in XP
patients [64]. These ﬁndings were consistent with the idea pro-
posed by several groups that XP is a repair syndrome, whereas TTD
is a transcription syndrome.
4. Genome Damage and Stability Centre
The MRC  CMU  was established by Bryn Bridges and it is a bizarre
policy of the MRC  that when the Director of a so-called ad per-
sonam Unit retires, the Unit is closed. Bryn was due to retire in
2001 and MRC  made it clear that the CMU  would not continue.
This left myself, Tony Carr and Penny Jeggo (who had joined us
in 1989) in a very uncertain position – during 1996–1998, we  did
not know where we were going to go. We  visited various uni-
versity departments around the country but were not happy with
anything that was on offer. This was a very unsettling period. Ulti-
mately Tony Moore, Dean of Life Sciences and subsequently Deputy
Vice-Chancellor at Sussex persuaded the university to provide us
with a new building and three university-funded senior positions.
For a small university like Sussex without any substantial ﬁnancial
assets, this was a major and risky commitment. MRC  then agreed
to fund the infrastructure of a joint University-MRC venture and
the Genome Damage and Stability Centre (GDSC) was established
in 2001 with myself as Chairman and Tony Carr as Director. In
the following years we were able to hire Keith Caldecott, Aidan
Doherty and more recently Jessica Downs to form a very strong
team focussed on DNA repair and genome stability. We  have been
delighted with the success of the GDSC, which has doubled in size
since its inception and now harbours 17 research groups.
5. PRR and TLS awake from a 20-year slumber
One of the few genes that had escaped identiﬁcation in the
1980s and 1990s was the gene defective in XP variants, but the ﬁeld
of postreplication repair was beginning to wake up again around
1998. Robert Fuchs contacted me  to tell me  that his postdoc Agnes
Cordonnier had developed a system for analysing TLS in human
cell-free extracts and they were eager to analyse TLS in XP variant
extracts. So we resurrected XPV cultures that had been in liquid
nitrogen storage for 25 years and Agnes was indeed able to demon-
strate a defect in TLS in XPV extracts [65]. Shortly afterwards, Roger
Woodgate (who had done his PhD at Sussex with Bryn Bridges in
1980s), told me  that he had found a gene related to Rad30 in yeast
that was a good candidate for the XPV gene. We  sequenced this
gene in several XPV cell lines but did not ﬁnd any mutations – the
gene turned out to encode DNA polymerase  [66], which is closely
related to polymerase , the real XPV gene that was  identiﬁed by
the Hanaoka and Prakash groups in June 1999 [67,68].
One week after the identiﬁcation of the XPV-pol gene had been
published, Patricia Kannouche joined my  lab on a grant which was
to clone the gene defective in XP-V cells! We  quickly had to rethink
the project and as Patricia had gained a lot of expertise on locali-
sation studies, she decided to analyse the localisation of pol.  This
was  a highly productive period and led to a series of publications on
the localisation of all of the Y-family DNA polymerases, ﬁrst pol
[69], subsequently pol in collaboration with Roger Woodgate [70],
Rev1with Robert Fuchs [71] and pol with Tomoo Ogi  [72].
Following on the discovery by Stefan Jentsch and colleagues that
PCNA was  ubiquitinated in S. cerevisiae when the replication fork
encountered DNA damage [73], Patricia decided to look if some-
thing similar happened in human cells. She found that it did indeed
and furthermore that ubiquitination of PCNA increased its afﬁnity
for pol, providing a nice model for switching from replicative to
TLS polymerase [74]. The following year, I was  contacted by Ivan
Dikic from Frankfurt, who  told me  that his student Magda Bienko
had discovered that the Y-family polymerases all bound to ubiqui-
tin and that, with Kai Hoffmann from Cologne, they had discovered
novel ubiquitin-binding domains in the Y family polymerases. This
led to an exciting and productive collaboration, in which Cath Green
in my  lab was able to complement the biochemical work by show-
ing the biological importance of the ubiquitin-binding domains in
these polymerases [75].
The work on TLS over the last 12 years has been particularly
exciting and I was  very gratiﬁed last year to be elected as a Fel-
low of the Royal Society. I have always sought to collaborate rather
than compete and my  work has beneﬁted hugely from many col-
laborations with other laboratories all over the world. These have
been stimulating both scientiﬁcally and personally. It goes without
saying that I am also indebted to the excellent postdocs, graduate
students and technicians who  have worked with me over the years.
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